{"brief_title": "A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer", "brief_summary": "This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal cancer. Patients will be randomized to receive either 1)XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2) FOLFOX-4 (oxaliplatin + leucovorin + 5-FU in 2 week cycles. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.", "condition": "Colorectal Cancer", "intervention_type": "Drug", "intervention_name": "capecitabine [Xeloda]", "description": "1000mg/m2 po bid on days 1-15 of each 3 week cycle", "arm_group_label": "XELOX", "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - metastatic colorectal cancer; - >=1 target lesion; - failed first-line chemotherapy with 5-fluorouracil and irinotecan. Exclusion Criteria: - previous treatment with oxaliplatin; - progressive or recurrent disease during or within 6 months of completion of first-line chemotherapy; - >=1 previous chemotherapeutic agent or systemic anticancer regimen for metastatic disease.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00069108.xml"}